Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19.

ABSTRACT:

Background

The use of remdesivir has demonstrated a significant reduction in the time to recovery in patients with COVID-19. However, the impact on mortality is still controversial. Therefore, it is necessary to evaluate whether there is a specific subgroup of patients in whom an active antiviral therapy also reduces the mortality.

Methods

Patients admitted for >48 h in our hospital for a SARS-CoV-2 confirmed or suspected infection from February 2020 to February 2021 were retrospectively analysed. The primary outcome of the study was mortality at 30 days. Univariate and multivariate analyses were performed to identify predictors of mortality.

Results

In total, 2607 patients (438 receiving remdesivir and 2169 not) were included with a median (IQR) age of 65 (54-77) yea

SUBMITTER: Garcia-Vidal C 

PROVIDER: S-EPMC8499897 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature